Semaglutide is approved as a long-term medication with no set end date. The FDA labels it for use “long term” in adults and adolescents with obesity, and major gastroenterology guidelines treat it the same way you’d treat blood pressure medication: as ongoing therapy for a chronic condition, not a short course you eventually stop.
That said, “you can stay on it indefinitely” raises practical questions about safety data, what happens if you stop, and whether insurance will keep covering it. Here’s what we know.
How Long Safety Data Actually Covers
The longest controlled data on semaglutide comes from the SELECT cardiovascular outcomes trial, where participants took the drug for roughly 31 to 59 months, depending on when they enrolled. That’s up to nearly five years of continuous use tracked under clinical trial conditions. The trial completed in mid-2023, and its results formed the basis for expanded FDA approvals.
Five years is a solid window for a relatively new drug class, but it does mean we don’t yet have 10- or 20-year data. For context, many widely prescribed medications were approved with far less long-term evidence. Your prescriber will monitor you with routine check-ins, partly to watch for any issues that only emerge over longer timeframes.
Why It’s Designed for Continuous Use
Semaglutide works by mimicking a gut hormone called GLP-1 that your body naturally produces after eating. It activates receptors in the brain’s appetite centers, reducing hunger signals so you eat less without feeling like you’re white-knuckling a diet. It also slows how quickly food leaves your stomach, which keeps you feeling full longer after meals. Some evidence suggests it increases the rate at which your body burns energy and fat as well.
These effects last only as long as the drug is in your system. Semaglutide doesn’t rewire your metabolism permanently or “reset” your appetite set point. It overrides signals that drive overeating, and when you remove it, those signals return. The American Gastroenterological Association’s clinical practice guideline frames obesity the same way clinicians frame high blood pressure or type 2 diabetes: a chronic illness where long-term pharmacological therapy is the standard approach for maintaining results.
What Happens When You Stop
This is the part most people searching this question really want to know. A 2026 systematic review in The Lancet’s eClinicalMedicine analyzed data from six randomized controlled trials covering over 3,200 participants who stopped GLP-1 receptor agonists. The finding was stark: one year after stopping, participants regained about 60% of the weight they had lost during treatment.
That regain isn’t a failure of willpower. When you lose a significant amount of weight, your body adjusts by increasing hunger hormones and lowering energy expenditure, essentially pushing you back toward your previous weight. Semaglutide counteracts those biological forces. Remove it, and the forces reassert themselves. This is the core reason obesity specialists recommend staying on the medication rather than treating it as a temporary fix.
Whether the Drug Loses Effectiveness Over Time
A common concern is whether your body builds tolerance, the way it can with certain pain medications. The available evidence is reassuring on this point. Semaglutide’s sustained activation of GLP-1 receptors appears to maintain its appetite-suppressing effects over the study periods we have data for. Most people reach their maximum weight loss somewhere between 12 and 18 months, then plateau. That plateau isn’t the drug “wearing off.” It reflects a new equilibrium where your lower body weight requires fewer calories, and the drug’s appetite suppression balances against your body’s drive to regain.
Some people do notice the appetite-suppressing effects feel less dramatic over time compared to the first few months. This is partly because the initial period involves dose escalation, where effects feel most noticeable, and partly because you adapt psychologically to your new baseline. The drug is still working; you’ve just gotten used to what “working” feels like.
Insurance and Cost Realities
The biggest practical limit on how long you can stay on semaglutide often isn’t medical but financial. Coverage varies widely. Medicare introduced a GLP-1 bridge program for 2026, but it requires prior authorization confirming the prescription is for ongoing weight maintenance. Medicaid coverage is even more inconsistent: only 13 states covered weight loss drugs as of January 2026, actually down from 16 states the year before, largely due to the high cost of these medications and state budget pressures.
Private insurance plans also vary. Some cover semaglutide indefinitely for qualifying patients, while others impose time limits, step therapy requirements (trying cheaper drugs first), or periodic reauthorization. If your coverage lapses or changes, the weight regain data above becomes personally relevant fast. It’s worth understanding your plan’s specific terms before assuming you’ll have uninterrupted access.
Reasons a Doctor Might Take You Off It
While semaglutide is intended for long-term use, there are situations where stopping makes sense. Persistent gastrointestinal side effects that don’t improve, particularly nausea or vomiting that interferes with nutrition, can prompt discontinuation. A history of or new symptoms suggesting pancreatitis, thyroid issues, or gallbladder disease may also lead your prescriber to reassess. Pregnancy or plans to become pregnant require stopping the drug well in advance.
Some people also reach a point where they’ve maintained their weight loss for years, adopted significant lifestyle changes, and want to try discontinuing with close monitoring. This is a reasonable conversation to have with your prescriber, though the data suggests most people will need to resume treatment if weight starts climbing back.